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Abstract
Background: Extracellular Hsp90 protein (eHsp90) potentiates cancer cell motility and invasion through a poorly
understood mechanism involving ligand mediated function with its cognate receptor LRP1. Glioblastoma multiforme (GBM)
represents one of the most aggressive and lethal brain cancers. The receptor tyrosine kinase EphA2 is overexpressed in the
majority of GBM specimens and is a critical mediator of GBM invasiveness through its AKT dependent activation of EphA2 at
S897 (P-EphA2S897). We explored whether eHsp90 may confer invasive properties to GBM via regulation of EphA2 mediated
signaling.
Principal Findings: We find that eHsp90 signaling is essential for sustaining AKT activation, P-EphA2S897, lamellipodia
formation, and concomitant GBM cell motility and invasion. Furthermore, eHsp90 promotes the recruitment of LRP1 to
EphA2 in an AKT dependent manner. A finding supported by biochemical methodology and the dual expression of LRP1
and P-EphA2S897 in primary and recurrent GBM tumor specimens. Moreover, hypoxia mediated facilitation of GBM motility
and invasion is dependent upon eHsp90-LRP1 signaling. Hypoxia dramatically elevated surface expression of both eHsp90
and LRP1, concomitant with eHsp90 dependent activation of src, AKT, and EphA2.
Significance: We herein demonstrate a novel crosstalk mechanism involving eHsp90-LRP1 dependent regulation of EphA2
function. We highlight a dual role for eHsp90 in transducing signaling via LRP1, and in facilitating LRP1 co-receptor function
for EphA2. Taken together, our results demonstrate activation of the eHsp90-LRP1 signaling axis as an obligate step in the
initiation and maintenance of AKT signaling and EphA2 activation, thereby implicating this pathway as an integral
component contributing to the aggressive nature of GBM.
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Introduction
High-grade astrocytoma (grade IV), or glioblastoma multiforme
(GBM), is the most common and lethal of human brain cancers
[1]. GBM’s poor prognosis is largely attributed to the highly
aggressive and infiltrative nature of these tumor cells, which invade
diffusely through the brain parenchyma [2], remain following
primary tumor resection [3,4], and contribute to tumor recurrence
and lethality. Therefore, alternative therapeutic modalities specif-
ically targeting and attenuating the invasive nature of GBM are
warranted.
Although numerous proteins support GBM aggressiveness,
interest in the pro-motility receptor tyrosine kinase EphA2
continues to intensify. EphA2 overexpression is common in
cancers, and is associated with oncogenic activity, cell invasiveness,
metastatic potential and poor prognosis [5]. Clinically, EphA2 is
highly overexpressed in a majority of primary and recurrent GBM
specimens [6,7,8], and is a significant predictor of adverse
outcome [7]. Although EphA2 is essential for facilitating GBM
cell motility and invasion in vitro [9,10], this activity is antagonized
by the EphA2 ligand ephrin A1 [6,9,11]. Ephrin A1 suppression is
frequently observed in breast and GBM specimens [6,12],
allowing these cancers to evade the restraint conferred by the
inhibitory ligand. In the absence of ligand, EphA2 facilitates cell
motility by coordinating signaling from a variety of RTKs via
growth factor mediated activation of AKT [10], which initiates
AKT-dependent EphA2 phosphorylation residue S897. This
activation, resulting in P-EphA2S897, is required for lamellipodia
formation and subsequent cell motility and invasion [10]. The
inhibitory effects of ephrin A1 correlate with a disruption of
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importance of AKT activation and EphA2-AKT interaction for
EphA2 oncogenic functions and support of GBM invasiveness.
We previously reported that the molecular chaperone heat
shock protein 90 (Hsp90) supports GBM cell motility, in part by
interacting with EphA2 and modulating receptor stability and
function [9]. Hsp90 has a well-established intracellular role in
mediating the folding and activity of numerous signaling proteins,
many of which contribute to malignancy [13,14,15]. Hsp90 is also
a reported tumor antigen [16,17], recently explained by its
extracellular localization. Mounting evidence implicates extracel-
lular Hsp90 (eHsp90) in cancer progression given its presence in
an expanding number of tumor cell types [18,19,20], and
involvement in metastatic spread [21,22,23]. Although the
mechanistic basis of its tumor-promoting function is not well
defined, eHsp90 elicits pro-motility and pro-invasive behavior
[19,20,21,22,24,25], in concert with LRP1 [26,27], a multi-
functional receptor activated by a diverse set of ligands [28]. We
now define a critical role for eHsp90 as a central regulator of
EphA2-dependent GBM cell motility through its ability to sustain
AKT activation and AKT-dependent activation of EphA2S897.
Moreover, we identify a new role for LRP1 as a co-receptor for
EphA2, a link strengthened by their protein interaction and co-
expression in GBM specimens. Therefore, our data illuminate a
novel crosstalk mechanism whereby eHsp90-LRP1 signaling is an
obligate step in AKT mediated P-EphA2S897 activation, an event
required for subsequent GBM cell invasion.
Results
eHsp90-LRP1 regulates EphA2 dependent motility and
invasion in GBM
Despite the emerging role for eHsp90 in cancer development,
nothing is known about its potential function in GBM. To
investigate whether eHsp90 supports GBM aggressiveness, two
approaches were utilized to block eHsp90 function. Treatment
with DMAG-N-oxide, a non-permeable GA (NPGA) derivative
specific for eHsp90 [21,29] potently inhibited G48a cell motility
(70%) (Figure 1A). Alternatively, antibody mediated neutralization
of eHsp90 function [21,22,30] similarly inhibited motility. These
effects were reproducible in other GBM cell lines (data not shown)
and highlight a pivotal role for eHsp90 function in supporting
GBM motility. eHsp90 signaling is transduced via the multifunc-
tional LRP1 receptor [26,27] and LRP1 has been implicated in
GBM cell motility and invasion [31]. LRP1 silencing [26], (Figure
S1A) blocked GBM cell motility in a manner similar to NPGA or
Hsp90 antibody treatments, with no further suppression elicited by
NPGA (Figure 1B). These results indicate that the pro-motility
function of eHsp90 in GBM is mediated through LRP1, a
conclusion further strengthened by similar trends obtained with
Boyden motility and Matrigel invasion assays (Figure 1C, D, and
Figure S1B, C).
To provide evidence for an eHsp90-LRP1 signaling complex in
GBM, we evaluated the surface expression of Hsp90 and LRP1 in
a panel of cell lines. Surface expression of Hsp90 and LRP1 was
elevated in three GBM cell lines (G48a, U87, U251) in comparison
to normal astrocytes (SVGA) (Figure S1D), trends consistent with
their Hsp90 secretion profile (Figure S1E). Interestingly, low
surface expression of Hsp90 in astrocytes correlated with its
nominal LRP1 surface expression; however, its total expression
level was comparable to that in GBM cells (Figure S1F), suggesting
that GBM cells may preferentially translocate LRP1 to the cell
surface. To explain the ability of NPGA to suppress signaling and
pro-motility function, we examined whether NPGA may attenuate
surface expression of eHsp90, As shown (Figure S1G), NPGA
decreased surface Hsp90 levels in G48a and U87 cells (4-fold and
3-fold, respectively), with no corresponding reduction of surface
LRP1 expression. The genetic silencing of LRP1 in G48a elicited a
comparable decrease in Hsp90 surface expression (5-fold),
strengthening the notion that surface Hsp90 levels correlate with
relative surface LRP1 expression. The ability of NPGA to reduce
surface expression of eHsp90 is therefore likely due to its ability to
interfere with eHsp90 interaction with LRP1. It is well established
GA has the capacity to dramatically alter the conformation of
intracellular Hsp90 [32]. Our data therefore suggest that eHsp90
associates with LRP1 in a conformationally specific manner and
that NPGA promotes an eHsp90 conformation incompatible with
LRP1 binding. This notion is supported by examples where
addition of agents capable of perturbing eHsp90 function
prevented the ability of eHsp90 to associate with binding partners
[19,20,23].
We, and others, have demonstrated that EphA2 plays a pivotal
role in coordinating GBM cell motility and invasion [6,9,10]. Given
our current data that eHsp90 and LRP1 are supporting partners of
GBM motility, we next investigated whether the eHsp90-LRP1
pathway crosstalks with EphA2 signaling. As expected, EphA2
silencing dramatically inhibited G48a cell motility and invasion
(Figures 1E, F). In support of crosstalk between the two signaling
axes, NPGA did not further inhibit cell motility or invasion in
EphA2 silenced cells (Figures 1E, F, Figures S2A-D). Taken
together, our data implicate eHsp90-LRP1 function as a critical
component of EphA2 driven motility and invasion.
Extracellular Hsp90 signaling regulates AKT activation,
subsequent AKT dependent EphA2 phosphorylation, and
lamellipodia formation
To further solidify the possibility of pathway crosstalk between
eHsp90 signaling and EphA2, we evaluated whether NPGA
specifically impacted upon EphA2 activation. To explore this, we
determined whether eHsp90 modulated the phosphorylation
status of EphA2S897. Perturbation of eHsp90 signaling by either
NPGA or LRP1 silencing effectively suppressed P-EphA2S897
(Figure 2A). EphA2 was recently identified as a substrate for AKT
in GBM, wherein AKT-directed phosphorylation of EphA2 at
S897 is required for EphA2 dependent cell motility [10]. NPGA
markedly suppressed, and LRP1 silencing abrogated, AKT
activation, demonstrating that perturbation of eHsp90 signaling
suppresses AKT activation and concomitant AKT mediated
phosphorylation of EphA2. AKT phosphorylation can be induced
by src [33], and we found that NPGA or LRP1 silencing
suppressed src activation (Figure S2E). To define the potential role
of src in modulating P-EphA2S897, src was silenced (Figure S2F),
which dramatically suppressed both P-AKTS473 and P-EphA2S897
(Figure 2A). This suggests that eHsp90-LRP1 mediated src
signaling is a prerequisite for subsequent serine phopshorylation
of AKT and EphA2.
Although treatment of cells with ephrin A1 ligand similarly
inhibited AKT activation and P-EphA2S897, src was induced by this
treatment (Figure S2G), an outcome consistent with other reports
[10,34,35]. Although this appears inconsistent with the ligand
independent role of src, the ability of ephrin A1 ligand to inhibit
AKT activation is reported to be src independent and to require
EphA2 kinase activity [35]. Regardless of this complexity, our
results support a model whereby suppression of AKT and P-
EphA2S897 represents a common mechanism by which eHsp90
inhibition and ephrin A1 blocks cell motility and invasion. These
inhibitory effects upon EphA2, AKT, and src were recapitulated by
addition of Hsp90a antibody (Figure S2G), supporting the notion
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that the effect of eHsp90 perturbation upon EphA2 signaling was
not due to a reduction of surface EphA2 expression (Figure S2H).
We next evaluated the consequences of the molecular changes
elicited by perturbation of eHsp90 signaling. Given that NPGA or
LRP1 silencing suppressed AKT-directed EphA2 phosphoryla-
tion, we examined whether eHsp90 modulated EphA2-AKT
complex formation. NPGA or LRP1 silencing potently abrogated
interaction between these proteins (Figure 2B). Ephrin A1
promoted a similar disruption of this complex, as expected [10],
supporting the notion that regulation of this complex is a central
component of GBM cell motility and invasion. As activation of
Figure 1. eHsp90-LRP1 regulates EphA2 dependent motility and invasion in GBM. Interference with eHsp90-LRP1 signaling inhibits GBM
cell motility and invasion. (A, B) Treatment of cells with NPGA (1 mM) or anti-Hsp90 antibodies (20 ug/ml) (A), or suppression of LRP1 (B) similarly
impaired G48a cell motility in wound healing assays. NS shRNA represents a nonspecifc shRNA control sequence. Percent migration is normalized to
the 16 hr control and values represent the mean 6 SD from 3 independent experiments (*p,0.001). (C) Serum starved parental or LRP1 silenced cells
were added to top chambers of a Boyden assay and serum induced chemotaxis initiated in the presence of vehicle or NPGA. Cell numbers represent
the mean 6 SD from five random fields (*p,0.001). (D) The effects of eHsp90 targeting upon cell invasion were assessed by a Matrigel assay in the
presence or absence of NPGA. Data is represented as the mean (6 SD) of three replicates. *p,0.001. (E–F) Interference with eHsp90 function does
not further inhibit cell motility or invasion in tandem with EphA2 silencing. G48a cells were transduced with either nonspecific (NS shRNA) or
shEphA2 and effects of NPGA upon cell motility assessed in Boyden (right panel), and invasion assessed by Matrigel (left panel).
doi:10.1371/journal.pone.0017649.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17649Figure 2. eHsp90-LRP1 signaling regulates activated EphA2 (phospho-S897), its association with AKT, and lamellipodia formation.
(A) Control or LRP1 silenced G48a cells were treated with NPGA, ephrin A1, or the combination, and the effects upon P-AKTS473 and P-EphA2S897 were
evaluated. The effect of src silencing was included for relative comparison. (B) Interference with eHsp90 signaling (NPGA or LRP1 silencing), or AKT
activation (src silencing or treatment with ephrin A1) disrupts EphA2-AKT protein complexes. (C) G48a cells grown were fixed 4 hr after wounding,
followed by immunostaining with the indicated antibodies. Arrows indicate the leading edge localization of P-EphA2S897 (a–c). Stimulation of cells
with ephrinA1 was included as positive control for suppression of EphA2S897 phosphorylation (d–f). Lamellipodia formation and concomitant
localization of P-EphA2S897 is similarly suppressed by NPGA (g–i) or LRP1 silencing (j–l), or by src silencing (m–o). Scale bars 25 mm.
doi:10.1371/journal.pone.0017649.g002
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determinants for the cell motility and invasion associated with
GBM [10], we next examined whether these treatments affected
P-EphA2S897 subcellular localization. Although P-EphA2S897 is
detected in lamellipodia in control cells following serum
stimulation (Figure 2C, panel a–c), ephrin A1 abrogated P-
EphA2S897 expression and lamellipodia formation (panels d–f), as
previously reported [10]. NPGA treatment or genetic silencing of
LRP1 or src, similarly abrogated receptor phosphorylation, and
lamellipodia formation (panels g–o).
ATPase deficient Hsp90 sustains AKT mediated EphA2
phosphorylation, lamellipodia formation, and cell
motility in the presence of NPGA
To further strengthen the premise that eHsp90 signaling is
essential for P-EphA2S897, we examined whether addition of
Hsp90 protein was sufficient as a stimulus to activate this pathway.
Addition of exogenous Hsp90a to serum starved G48a cells
robustly stimulated phosphorylation of src, AKT and EphA2
(Figure 3A). The N-terminal ATPase domain of Hsp90 is
dispensible for its extracellular pro-motility functions [26]. Our
data support this notion, as addition of an N-terminally truncated
Hsp90 protein (D1-235 aa) lacking its ATPase domain
(Hsp90DATP) [26] activated P-srcY416, P-AKTS473 and P-
EphA2S897 to an extent comparable to that of the wild type
Hsp90a protein (Figure 3A). To validate the specificity of NPGA’s
effects upon eHsp90, we utilized NPGA in tandem with
Hsp90DATP. Since the truncated protein lacks the NPGA binding
pocket, this protein should not undergo a drug mediated
conformational change and would therefore be expected to be
resistant to the effects of drug. In support of this premise,
Hsp90DATP rescued cells from NPGA’s suppressive effects upon
src, AKT and EphA2. Moreover, the ability of Hsp90DATP to
preserve P-AKTS473 upon drug challenge further illustrates the
specificity of NPGA for eHsp90, as cell permeable Hsp90
inhibitors suppress AKT activation [36]. We next examined
whether the Hsp90DATP mediated activation of EphA2 and AKT
correlated with its ability to foster association between these
proteins. Hsp90DATP sustained EphA2-AKT complexes during
challenge with NPGA (Figure 3A), and elicited a modest increase
in their association, indicating that eHsp90 expression influences
the magnitude of downstream signaling and augment the affinity
of EphA2 for its binding partners.
We next performed a more thorough analysis to determine the
extent to which Hsp90DATP protected cells from NPGA’s
suppressive effects. Interestingly, both wild type and Hsp90DATP
protein comparably increased G48a cell invasion by two-fold.
However, whereas NPGA treatment abrogated cell motility and
invasion of cells fortified with native protein, Hsp90DATP rescued
cells from these inhibitory effects (Figure 3B and Figure S3A, B).
We extended the relevance of these findings by evaluating P-
EphA2S897 and lamellipodia formation in intact cells. Addition of
native or Hsp90DATP protein to starved G48a cells potently
stimulated P-EphA2S897 and lamellipodia formation (Figure S3C
panels d–f, j–l). Importantly, while NPGA suppressed P-
EphA2S897 in the presence of native protein, this agent had no
inhibitory effects upon cells treated with Hsp90DATP, evidenced by
the retention of both P-EphA2S897 and lamellipodia formation
(panels g–i and m–o). These data are congruous with our
molecular data (Figure 3A), and strongly implicate activation of
P-AKTS473 and P-EphA2S897 as essential components of eHsp90-
dependent lamellipodia formation and cell motility and invasion.
To further test the premise that eHsp90 mediated activation of
AKT was essential for its pro-motility function, we next examined
whether constitutive activation of AKT would antagonize the
effects of NPGA. To explore this, G48a cells were transduced with
constitutively active myristolated AKT (Myr-AKT) proteins [37].
Myr-AKT1 and Myr-AKT2 maintained their activated P-AKT
status when challenged with drug, as well as their interaction with
P-EphA2S897 (Figure 3C). Interestingly, although these three
isoforms share a large degree of homology [38], Myr-AKT3 did
not sustain its activation status, P-EphA2S897 expression, or
interaction between EphA2 and AKT following NPGA challenge.
Importantly, the ability of AKT isoforms to maintain P-EphA2S897
occurs concomitantly with their ability to rescue cells from the
anti-motility effects of NPGA. Myr-AKT1 and Myr-AKT2
transduced cells retained their motile properties in the presence
of NPGA, while motility was suppressed in drug treated Myr-
AKT3 transduced cells, concordant with suppressed Myr-AKT3
activation (Figure 3D, Figure S3D). While the basis of NPGA
mediated inactivation of Myr-AKT3 is currently unknown, our
results are consistent with the premise that eHsp90 mediated
activation of AKT is an essential component of EphA2 directed
cell motility.
Hypoxia stimulates GBM motility and invasion via
amplified eHsp90-LRP1 signaling and consequent
activation of AKT and EphA2
Tumor hypoxia, a hallmark of GBM [39], is a well known
enhancer of cell motility and invasiveness [24,40]. As hypoxia
induces both Hsp90 secretion and cell motility [24], we
investigated whether hypoxia utilizes eHsp90 dependent signaling
to promote GBM motility and invasion. Hypoxia elicited a 2.5-
fold increase in Hsp90a secretion in G48a cells, with similar
dramatic increases observed in U87 and U251 GBM cells
(Figure 4A). Furthermore, hypoxia increased surface expression
of both Hsp90 and LRP1 (4-fold and 5-fold, respectively)
(Figure 4B). Interestingly, cellular expression of both LRP1 and
Hsp90a was also elevated (2-fold, and 1.5 fold, respectively). To
examine whether hypoxia-mediated increases in eHsp90 and
LRP1 amplified the eHsp90-LRP1 signaling axis, we surveyed the
activation status of the signaling intermediates src, AKT and
EphA2. Hypoxia robustly activated src, AKT and EphA2 (11.4,
5.6, and 8.4-fold, respectively) (Figure 4C), and concomitantly
induced cell motility (40%) and invasion (3.5-fold) (Figure 4D,
Figure S4A, B). Strikingly, NPGA completely abrogated hypoxia
stimulated activation of src, AKT, and EphA2, and suppressed cell
motility and invasion (Figure 4D, Figure S4A, B). These results
clearly demonstrate that hypoxia dependent upregulation of
surface LRP1 and Hsp90 potentiate eHsp90-LRP1 signaling to
facilitate AKT activation and subsequent EphA2 directed cell
motility.
LRP1 is a co-receptor for EphA2 and co-localizes with P-
EphA2S897 in clinical GBM specimens
Given that LRP1 is required for eHsp90 dependent EphA2
activation, we next investigated whether this regulation is
mediated by a physical interaction. To explore this, U87 cells,
which express high levels of LRP1 (Figure S1F), were transduced
with HA-tagged EphA2 plasmids. Interestingly, we demonstrate a
robust association between LRP1 and EphA2 in untreated cells.
This interaction is similarly disrupted by treatments that suppress
AKT activation (NPGA, PP2, or ephrin A1), (Figure 5A). Given
that AKT activation facilitates P-EphA2S897, we next asked
whether phosphorylation of S897 on EphA2 was required for its
interaction with LRP1. To examine this, we utilized an EphA2
point mutant protein (S897G), which is not recognized by the
eHsp90-LRP1 Regulates EphA2 Dependent GBM Invasion
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EphA2S897G was unable to interact with LRP1, reinforcing our
hypothesis that the AKT consensus site of EphA2 represents a
critical recognition motif required for its interaction with LRP1.
To further examine the potential co-receptor function of LRP1,
we next utilized fluorescence microscopy to determine the
proximity of LRP1 and EphA2 in cells. In support of our
biochemical results, EphA2 and LRP1 exhibited a significant
Figure 3. Preservation of AKT activation is required for lamellipodia formation, and concomitant cell motility and invasion. (A)
Serum starved (8 hr) G48a cells were exposed to either native or Hsp90DATPase proteins (3 mg/ml) for 15 min in the presence or absence of NPGA, and
the indicated signaling molecules evaluated by immunoblot. The effect of these treatments upon EphA2-AKT interaction was also evaluated. (B) A
Matrigel invasion assay was utilized to evaluate the ability of native or Hsp90DATPase proteins to sustain cell invasion in the presence of NPGA. Values
represent the mean (6 SD) of 3 independent experiments. (C) G48a cells stably transduced with the indicated HA-tagged myristolyated AKT
constructs were exposed to NPGA and HA immunopurified complexes were evaluated for P-AKT and P-EphA2S897. (D) The pro-motility function of the
indicated AKT proteins was evaluated in the presence or absence of NPGA using a scratch wound assay.
doi:10.1371/journal.pone.0017649.g003
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17649Figure 4. Hypoxic conditions amplify eHsp90-LRP1 initiated AKT-EphA2 signaling. (A) The ability of hypoxia to modulate Hsp90a
secretion was determined by ELISA, as in Supplementary Figure S1E. (B) G48a cells cultured in 1% serum were exposed to hypoxia (1% O2) for 36 hr
and surface expression of Hsp90a and LRP1 was determined in intact cells by flow cytometry. A corresponding immunoblot shows total cellular
expression of LRP1 and Hsp90a. (C) Representative immunoblot demonstrating effects of hypoxia upon activation of src, AKT, and EphA2 in the
presence or absence of NPGA. (D) A Matrigel invasion assay was utilized to evaluate the effects of hypoxia (16 hr) upon cell invasion in the presence
or absence of NPGA.
doi:10.1371/journal.pone.0017649.g004
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17649Figure 5. LRP1 is a co-receptor for EphA2 and co-localizes with P-EphA2S897 in clinical GBM specimens. (A) HA-EphA2 transfected U87
cells were treated with NPGA, ephrin A1, or the src inhibitor PP2 for 16 hr. LRP1 was detected from HA immunoprecipitates. (B) U87 cells were
transfected with HA-tagged wild type or point mutant (S897G) EphA2 plasmid, and LRP1 was detected from HA immunoprecipitates. (C) U87 cells
were immunostained with indicated antibodies showing that LRP1 co-localized with EphA2. Scale bar 25 mm. The bottom panels represent magnified
areas of confocal images derived from the respective upper panels, as delineated by the boxed region. Scale bar 5 mm. (D) Detection of P-EphA2S897
and LRP1 in human GBM specimens. Panels a–f, and m–o are paraffin sections, panels g–l are frozen specimens. Magnification6200. Lower panels (a–
l) are paraffin sections from the recurrent GBM specimens. Magnification 6400.
doi:10.1371/journal.pone.0017649.g005
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of GBM cells. To explore the clinical relevance of this finding, we
examined the pattern of LRP1 and EphA2 staining in serial
sections derived from clinical GBM specimens, and observed a
consistently overlapping pattern of LRP1 and P-EphA2S897
(Figure 5D, top panel, a–f). Expression of P-EphA2S897 has been
reported within areas of vascularity in GBM specimens [10], and
we similarly observe P-EphA2S897 in the microvasculature, along
with prominent perivascular immunoreactivity for LRP1 (panels
g–l). In the lower set (panels j–l, indicated by arrows), an
overlapping staining pattern of LRP1, EphA2, and P-EphA2S897
is visible at the periphery of a blood vessel, as well as within the
vessel lumen, indicative of cell invasion. The consistent trends of
expression of these proteins within similar proximity strongly
suggest a functional interaction in GBM. BTCOE specimens
3175, 4460, 4591, and 4485 were derived from recurrent GBM.
In contrast to the modest expression of P-EphA2S897 and LRP1
in GBM tissues, nominal expression was noted in normal brain
tissue (panels m and o), and EphA2 expression was similarly weak
(panel n). To evaluate the prevalence of LRP1 expression in GBM,
we examined a larger cohort (75) of GBM specimens. While the
majority (91%) of normal tissues was negative for LRP1, 68% of
Grade IV GBM tissues exhibited moderate to high expression
(Table 1). Fisher’s exact test indicated a statistically significant
association between sample type and LRP1 expression level
among these groups (P,0.001). These data support a prior report
documenting higher LRP1 expression in a variety of brain derived
neoplasms [41]. Our data strengthen the notion that LRP1
contributes to the pathological nature of this disease, in large part
via promotion of EphA2 dependent signaling.
Discussion
Extracellular Hsp90 is emerging as a pivotal regulator of cell
motility, invasion, and metastasis. Although the precise mecha-
nisms of eHsp90 function remain largely unknown, eHsp90
regulates several well-established pro-motility molecules
[19,21,23,27]. Our current study linking eHsp90 signaling with
EphA2-dependent cell motility and invasion adds a unique
dimension to eHsp90’s pro-tumorigenic repertoire. To our
knowledge, this is the first report linking eHsp90-LRP1 signaling
with EphA2 function. We show that eHsp90 promotes the
recruitment of LRP1 to EphA2 in an AKT dependent manner
and further demonstrate the previously unknown ability of LRP1
to exhibit specificity for a subset of AKT substrate proteins. Our
data support a model whereby eHsp90-LRP1 dependent signaling
is an obligate step for AKT activation and subsequent AKT
directed phosphorylation of EphA2. This premise is supported by
the shared ability of ephrin A1 ligand, NPGA or LRP1 silencing to
suppress the phosphorylation of both AKT and EphA2, and to
disrupt association between EphA2 and LRP1, culminating in the
abrogation of lamellipodia formation and cell motility and
invasion (Figure 6). Our studies therefore highlight a dual role
for eHsp90 in transducing signaling via LRP1, while additionally
promoting its LRP1 co-receptor functions to modulate EphA2
signaling, Recent reports highlighting the ability of eHsp90-LRP1
to elicit pro-motility function in normal and cancer cells [27,42]
portends a widespread role for this signaling pair in a variety of
cancers that express EphA2. Whether eHsp90-LRP1 similarly
regulates additional pro-motility receptors and intermediates is an
area of active investigation.
The role of LRP1 in cell motility is controversial, with some
reports documenting pro-motility function [24,26,27,42], while
others document anti-motility function [43]. These disparate
reports may be ascribed to LRP1’s complex role as both an
endocytic and signaling receptor, coupled with its interaction with
a diverse set of ligands [28]. Although LRP1 has been reported to
confer pro-motility function in GBM cells [31] its mode of action is
not well defined. Although we cannot exclude the possibility that
eHsp90 influences LRP1 endocytic function, our data support a
model whereby eHsp90-LRP1 functions as a signal transduction
complex to regulate src dependent AKT phosphorylation,
resulting in P-EphA2S897 directed cell motility and invasion.
Interestingly, although a recent report demonstrated a require-
ment for eHsp90-LRP1 signaling in the motility and invasion of
colon cancer cells, AKT did not participate in eHsp90 pro-motility
function [27]. This example, in stark contrast to our model,
highlights the signaling complexity inherent in cancer, and the
ability of tumor cells to acquire dependence upon discrete
components of eHsp90’s signaling repertoire.
Our results implicate a role for eHsp90-LRP1 in serving as a
central rheostat in controlling the amplitude of downstream
signaling events. This was exemplified by the ability of eHsp90
protein to robustly induce the phosphorylation of src, AKT, and
EphA2, concomitant with increased cell invasion. Importantly, we
now show that eHsp90 signaling is amplified during cellular
hypoxia, a well defined enhancer of cell motility and invasiveness
in both normal and cancer cells [24,40]. Hypoxia induces LRP1
gene expression in a number of cell types [44], although the
physiological significance of this event has remained enigmatic.
We show that hypoxia significantly increases the surface
expression of both LRP1 and eHsp90, thereby amplifying the
eHsp90-LRP1 signaling axis, evidenced by robust activation of src,
AKT and EphA2, accompanied by enhanced cell motility and
invasion. Strikingly, perturbation of eHsp90 function eliminates
the hypoxia-mediated activation of these signaling intermediates
and potently suppresses motility and invasion. Therefore, our data
support the premise that the hypoxic potentiation of src/AKT/
EphA2 activation is inextricably dependent upon eHsp90 directed
cell motility and invasion.
Clinically, tissue hypoxia is a major contributor to several
pathological features of GBM [45,46], and our data implicate the
hypoxic microenvironment of GBM as a significant potentiator of
eHsp90-LRP1 signaling and GBM tumor cell aggressiveness.
Given that AKT activation and expression of P-EphA2S897 are
prevalent events in primary and recurrent GBM [10,47,48], and
our data implicating LRP1 upregulation in clinical specimens, a
model is proposed whereby GBM tumors amplify both eHsp90-
LRP1 and AKT-EphA2 signaling axes to create a synergistic feed
forward circuit that supports GBM aggressiveness. Our current
findings significantly expand the known functions of eHsp90-
LRP1 in malignancy and define crosstalk with AKT-EphA2 as a
Table 1. Distribution of LRP1 expression in normal and GBM
specimens.
Expression Normal (%) Glioblastoma (%) Total (%)
Negative 21 (91) 7 (9) 28 (29)
Low 2 (9) 17 (23) 19 (19)
Moderate 0 (0) 30 (40) 30 (31)
High 0 (0) 21 (28) 21 (21)
Total 23 (100) 75 (100) 98 (100)
Histopathological scoring is as follows: negative staining (0), weak staining (1),
moderate (2–3), and strong (4–5). Fisher’s exact test suggests a strong
association between sample type and LRP1 expression level (p,0.001).
doi:10.1371/journal.pone.0017649.t001
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function in GBM. These unique insights into the effector
molecules governing eHsp90 dependent invasive function in
GBM highlight new approaches to curtail the aggressiveness
associated with this malignancy.
Materials and Methods
Antibodies and Reagents
Antibodies to P-srcY416 (2101), src (2108), P-AKTS473 (4058),
and AKT (9272) were purchased from Cell Signaling; goat and
mouse EphA2 antibodies (AF3035, MAB3035) were from R&D
Biosystems; Rabbit P-EphA2S897 anitbody was produced in Dr.
Bingcheng Wang’s laboratory [10] HA conjugated beads
(11815016001) were from Roche; Protein G agarose beads
(15920-010) were from Invitrogen, anti-phosphotyrosine antibody
(PY20) was from Santa Cruz; mouse and rabbit Hsp90 antibodies
(ADI-SPA-830, ADI-SPS-771) were from Assay Designs, and anti-
alpha tubulin antibody (T6074) was from Sigma. The PE
conjugated anti-Hsp90 (ADI-SPA-830PE) antibody was from
Assay Designs and conjugated antibodies Alexa fluor 488
phalloidin (A12379) and 546 phalloidin (A22283) were from
Invitrogen. Fluorescently conjugated secondary antibodies were
purchased from Invitrogen (A-11001, A-11003, A-21050,
A110055, A11008). Mouse monoclonal LRP1 antibody (11H4)
was purified from a hybridoma cell line (CRL 1936) purchased
from ATCC. The hybridoma supernatant was concentrated with a
Vivacell 70 concentrator (Sartorius Biolab products) and purified
with an NAb protein G antibody purification kit (Thermo
Scientific) according to the manufacturer’s instructions, and
aliquots were stored at 220uC. Recombinant ephrin-A1-FC
(602-A1-200) was purchased from R&D Biosystems. PP2
(529573) was from Calbiochem. Recombinant Hsp90 protein
was obtained from Assay Designs (ADI-SPP-776). Geldanamycin
was obtained from the Experimental Therapeutics Branch,
National Cancer Institute, DMAG-N-oxide modified geldanamy-
cin, (or non-permeable GA, NPGA) was synthesized by Zuping
Xia (Pharmaceutical Sciences, Medical University of South
Carolina).
Cell Culture
The GBM cell lines U251 and U87 were obtained from ATCC,
G48a and SV40 immortalized astrocytes were provided by
Waldemar Debinski and Ashok Chauhan, respectively, and
Figure 6. Molecular crosstalk between eHSP90-LRP1 and AKT-EphA2 signaling. An eHSP90/LRP1 signaling axis is required to sustain src
directed AKT activation, AKT dependent P-EphA2S897, and LRP1 recruitment to EphA2. These signaling events facilitate lamellipodia formation and
support GBM cell motility and invasion. Hypoxia amplifies eHsp90 signaling and corresponding motility via enhanced LRP1 expression and Hsp90
secretion. NPGA inhibits eHsp90 signaling, with consequent inhibition of AKT, disruption of EphA2 and LRP1 complexes, and blockade of cell motility.
ephrin A1 ligand similarly suppresses AKT activation, P-EphA2S897, EphA2-LRP1 complexes, and elicits comparable inhibitory effects upon GBM cell
motility and invasion.
doi:10.1371/journal.pone.0017649.g006
eHsp90-LRP1 Regulates EphA2 Dependent GBM Invasion
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17649HA-AKT1-3 plasmids provided by Carola Neumann. The viral
packaging cell line 293FT was from Invitrogen. Cells were
maintained in their specified medium, supplemented with 10%
fetal bovine serum, 1% HEPES and 1% penicilin/streptomycin in
a5 %C O 2-humidified atmosphere.
Plasmids, siRNAs, and transfections
To construct HA-EphA2S897G, the following primers were used:
GTGTCTATCCGGCTCCCCGGCACGAGCGGCTCGGAG-
G (upper), and CCTCCGAGCCGCTCGTGCCGGGGAGCC-
GGATAGACAC (lower). Primers were annealed to a wild type
HA-EphA2 plasmid, and PCR was performed with PfuUltra HF
DNA polymerase (Stratagene). Nonmutated parental DNA was
cleaved with DpnI restriction enzyme and the reaction mix was
used to transform XL1-Blue supercompetent bacteria. DNA was
harvested from resultant clones and processed for sequence
validation of the point mutation. Lentiviral particles against src,
or nonspecific sequences, were purchased from Santa Cruz. To
silence src, cells were infected with the viral particles (1:200
dilution) in the presence of polybrene (8 mg/ml), and selection was
performed with puromycin (Invivogen) for two weeks, whereupon
surviving cells were pooled. To obtain shRNA viral particles for
LRP1 and EphA2, 293FT cells were co-transfected with the viral
packaging plasmids VSVG and PDR 8.71, along with either
shLRP1 or shEphA2. The cell medium was harvested at 48 hr the
lentiviral supernatant was concentrated by ultracentrifugation,
tittered, and 5610
4 particles were used to infect the recipient cells.
Cells transduced with shEphA2 were selected in puromycin, while
flow cytometry was used to isolate the highest expressing (95%)
GFP-shLRP1 transduced cells. This selected population remained
stable over time. All plasmid tranfections were performed with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
specifications.
Cell motility and invasion assays
For cell wounding assays, a thin sterile pipette tip was used to
create a scratch wound in confluent cell monolayers cultured in
full serum. Pictures were taken at 0 and 24 hrs with an inverted
Nikon eclipse TE 2000-S microscope with 106magnification, and
the extent of migration was calculated by measurement of the gap
area using Image J software. For analysis of directional cell
motility, chemotactic cell migration was carried out in modified
Boyden chambers as previously described [9] with 2610
4 cells.
The mean value from 5 fields per chamber was calculated from
three independent experiments. Invasion assays were performed
with 8-mm 24 well MatriGel-coated Transwell inserts (BD
Biosciences) Inserts were rehydrated with medium for 2 hr at
37uC. Prior to plating, cells were serum starved for 16 hrs, and
4610
5 cells were subsequently plated in 0.1% serum containing
medium. After incubation at 37uC for 16 hr cells were fixed and
stained with 0.5% crystal violet. For all motility and invasion
experiments, mitomycin C (5 ug/ml) (Sigma) was added at the
time of plating to suppress proliferation. Cells migrating through
both the Matrigel and the filter pores were counted from 5
random fields from 3 wells and represented as a mean (6 SD) of
three replicates. P value less than 0.05 was considered significant.
Flow Cytometery
Cells were trypsinized, washed with PBS, blocked (0.1% sodium
azide, 2% bovine serum albumin/PBS), and Hsp90 was detected
with PE conjugated antibody, EphA2 was detected with anti-goat
antibody and LRP1 was detected with the mouse 11H4 antibody,
all diluted 1:50 in blocking buffer. Washed cells were then
incubated with the appropriate labeled secondary antibody and
resuspended in PBS. Data were acquired with a FACS Calibur4-
color flow cytometer (BD, Biosciences), and analyzed with FlowJo
software (TreeStar). A minimum of 10,000 cells was counted per
experiment. Negative controls consisted of cells incubated either in
the complete absence of antibody or with isotype matched
secondary antibody alone. The mean fluorescence intensity
(MFI) of the signal was calculated by Flow Jo software and signal
obtained from EphA2 and LRP1 was normalized with that
obtained from isotype controls.
Western blot and Immunoprecipitation
Cell extracts were prepared as described [11]. For immuno-
precipitation experiments, cells were lysed (10 mM Tris pH7.4,
150 mM NaCl, 0.5% NP40, 10% glycerol, 2 mM EDTA with
protease inhibitor cocktail (Roche), immunoprecipitates eluted
with 66SDS loading dye, and densitometric analyses performed
with ImageJ software.
Hypoxic treatment
For hypoxia treatments, cells were placed within an enclosed
bactron anaerobic chamber (Shel Lab) containing a 37uC
temperature controlled incubator. The incubator was humidified
with a water tray and the oxygen concentration was maintained
via regulated infusion of premixed gas (94% N2,5 %C O 2, and 1%
O2). The oxygen concentration within the chamber was
continuously monitored.
Hsp90a ELISA
To detect expression of secreted Hsp90a, equivalent cell
numbers (2610
5) were plated overnight and replenished with
complete media 24 hr prior to harvest. Conditioned medium was
collected, debris removed by centrifugation (5 min, 1200 x g) and
Hsp90 levels detected with an Hsp90a ELISA kit (Assay Designs).
Background values (from control medium) were subtracted from
readings (examined in triplicate) and values are presented as the
average ng of Hsp90 per ml of conditioned medium with the
standard deviation shown.
Immunohistochemistry
Banked tissues were acquired through the Hollings Cancer
Center Tissue Biorepository (Medical University of South
Carolina), or the Wake Forest Brain Tumor Center of Excellence
(BTCOE). Commercial GBM TMAs (T171, GL805, GL2083)
were obtained from US Biomax, Inc. Embedded tissues were
deparaffinized and antigen retrieval was performed with Target
Retrieval Solution (DAKO, Carpinteria, CA) coupled with
steaming. Banked frozen GBM tissue was serially sectioned
(5 mm), fixed in acetone, hydrated in PBS and subjected to
immunostaining. The slides were incubated with the indicated
primary antibodies: goat polyclonal EphA2 (1:500), P-EphA2S897
(1:500), LRP1 (11H4, 1:500–1:1000) and signal visualized with a
biotinylated secondary antibody (1:200) and streptavidin biotin
peroxidase kit (DAKO LSAB+ System-HRP), along with a DAB
chromagen and peroxide substrate. For BTCOE images, immu-
nostaining was visualized using an ABC Elite Kit (Vector Labs)
followed by DAB without nickel (black, EphA2), DAB (brown,
LRP1) or VectorRed (P-EphA2S897) as the chromagen (Vector
Labs). For negative control immunostaining, nonspecific, species
matched biotinylated antibodies were added in tandem in the
absence of primary antibody. All final images were independently
verified by a pathologist as representing similar fields from
adjacent tissue sections. Images were acquired at 2006 magnifi-
cation with an Eclipse 55i Nikon Digital photomicroscope system,
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assessment, pathological scoring was performed - negative staining
(0), weak staining (1), moderate (2–3), and strong (4–5). Fisher’s
exact test was used to analyse association between sample type and
LRP1 expression level. P value less than 0.05 was considered as a
significant.
Immunofluorescence
To image lamellipodia formation, confluent monolayers were
scratch wounded, and 4 hr later, cells were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100 in
PBS. Immunofluorescence was performed as described in [11].
Statistical analysis
All cell motility and invasion experiments were performed in
triplicate. Data shown are presented as means 6 SD; differences in
treatment groups are defined as statistically significant at P,0.05
value, as calculated from Student’s t test.
Supporting Information
Figure S1 Interference with eHsp90 signaling inhibits
GBM cell motility and invasion. (A) Relative degree of LRP1
suppression in stably selected LRP1 silenced G48a cells. LRP1 was
immunodetected from equivalent amounts of lysate. (B) GBM cell
motility is inhibited by either LRP1 silencing or NPGA treatment
(16 hr). Representative images from Boyden cell motility exper-
iments. Serum within the lower wells served as the chemoat-
tractant. (C) GBM cell invasion is suppressed by either LRP1
silencing or NPGA treatment. Representative images from
Matrigel invasion assays, performed with conditions as above.
(D) Surface expression of Hsp90 and LRP1 is elevated in GBM as
compared to normal astrocytes. eHsp90 and LRP1 were detected
in the indicated GBM cell lines (G48a, U87, U251) or
immortalized astrocytes (SVGA) by flow cytometric analysis of
nonpermeabilized cells. Surface Hsp90 was visualized with PE
conjugated Hsp90 antibody, relative to matched isotype control,
and LRP1 detection was facilitated with anti-LRP1 antibody,
followed by fluorescently labeled secondary antibody. Positively
stained cells are represented as the area under the respective
histogram, and mean fluorescence intensity (MFI) values are
shown. (E) Hsp90a is secreted from GBM cell lines. An ELISA
assay was utilized to detect the levels of Hsp90a in conditioned
medium from equivalent cell numbers (1610
6). (F) Relative
cellular expression of LRP1, Hsp90a, and EphA2 in SVGA and
GBM cell lines. Cell extracts were harvested from the indicated
panel of cell lines and tubulin was used as a protein loading
control. (G) Surface Hsp90 expression is diminished by either
LRP1 silencing or NPGA treatment. Flow cytometric analysis was
performed as in D, except that, where indicated, cells were treated
with NPGA for 16 hr prior to analysis. Surface Hsp90 expression
was relatively proportional to surface LRP1 expression, as
demonstrated by LRP1 silencing. Although NPGA reduced
surface Hsp90 expression, surface LRP1 expression was not
affected.
(TIF)
Figure S2 eHsp90-LRP1 regulates EphA2 dependent
motility, invasion and signaling. (A) Representative immu-
noblot showing the extent of EphA2 suppression following stable
transduction of shEphA2 in G48a cells. (B) Analysis of the effects
of EphA2 silencing upon G48a cell motility in the presence or
absence of NPGA. Confluent monolayers of parental or EphA2
silenced cells were scratched and representative images of
wounded areas are shown from time 0 and 16 hr post wounding.
The graph is represented as the mean (6 SD) of three replicates.
*p,0.001. (C, D) The anti-motility and anti-invasive effects of
NPGA upon parental and EphA2 silenced cells were evaluated
with Boyden chamber (C) or Matrigel (D) assays. Experiments
were performed as in Figures 1C and 1D, and representative
images shown. (E) Interference with eHsp90 signaling by NPGA or
LRP1 silencing suppressed src phosphorylation. (F) Representative
degree of src suppression following stable transduction of src
shRNA lentiviral construct in G48a cells. (G) Antibody-mediated
Hsp90 targeting suppresses P-srcY418, P-AKTS473 and P-
EphA2S897. G48a cells were incubated for 16 hr with either
control antibody (IgG), or anti-Hsp90a antibody (SPS-771, 20 ug/
ml) followed by immunoblot analysis for the indicated proteins.
Where indicated, ephrin A1 was added 10 min prior to cell lysis.
(H) Interference with eHsp90 signaling does not alter surface
EphA2 expression. Flow cytometry was performed on intact G48a
cells to compare EphA2 surface expression in parental G48a cells,
relative to LRP1 silenced or NPGA treated cells (16 hr). EphA2
protein was detected by a rabbit polyclonal antibody recognizing
an extracellular epitope, followed by fluorescently labeled anti-
goat antibody. Representative histograms of EphA2 staining are
shown. A fluorescently labeled isotype matched control antibody
was included to demonstrate EphA2 signal specificity.
(TIF)
Figure S3 Preservation of AKT activation is required for
lamellipodia formation, and concomitant cell motility
and invasion. (A) A scratch wound assay was utilized to evaluate
the ability of either native or Hsp90DATP to rescue G48a cell
motility in the presence of NPGA. Cells were treated with either
native or Hsp90DATP proteins (3 mg/ml) for 16 hr and represen-
tative images (106 magnification) are shown. The graph is
represented as the mean (6 SD) of three replicates. *p,0.001. (B)
Native or Hsp90DATP proteins (3 mg/ml) were added (top and
bottom wells) to serum starved G48a cells in a Matrigel invasion
assay. Representative images are shown. (C) The indicated Hsp90
proteins were added (15 min) to serum starved G48a cells 4 hr
post cell wounding, as in Figure 2C. Cells were continuously
exposed to NPGA 16 hr prior to fixation. Expression of P-
EphA2S897, F-actin, and the co-localization of these proteins were
analyzed by confocal microscopy. Scale bar is 25 mm. (D) A
scratch wound assay was utilized to evaluate the ability of
constitutively active (myristolyated) AKT isoforms to sustain G48a
cell motility in the presence of NPGA. Cells were treated as in
Figure S2B and representative images shown.
(TIF)
Figure S4 Hypoxia stimulates GBM motility and inva-
sion via eHsp90 dependent signaling. (A) The effects of
hypoxia upon G48a cell motility was evaluated in either the
presence or absence of NPGA by scratch wound assay, Data is
represented as the mean (6 SD) of three replicates. *p,0.001. (B)
Cell invasion was determined by a Matrigel assay following
exposure of G48a cells to normoxia or hypoxia (1% O2) for 16 hr
in the presence or absence of NPGA. Representative images are
shown.
(TIF)
Figure S5 Point mutated HA-EphA2S897G is not recog-
nized by the P-EphA2S897 specific antibody. U87 cells were
transiently transfected with the indicated HA-tagged EphA2
plasmids, and EphA2 activation status was evaluated by pro-
bing HA immunopurified extracts with P-EphA2S897 antibody.
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total cellular lysate with HA antibody.
(TIF)
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